Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic ...

We recently published a list of Top 10 Stocks Everyone Is Talking About These Days. In this article, we are going to take a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus ...

Tempus AI (TEM) announced it has acquired Deep 6 AI. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate ...

Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests ...

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX ...

Before the acquisition, Ambry served as Tempus' largest reference laboratory for hereditary cancer screening, and the companies had entered a strategic collaboration to provide a combined ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and market outlook.

Tempus AI, Inc. (NASDAQ ... advances in understanding the biology of FL patients who are at high risk of cancer progression and enhancing therapeutic development to address critical unmet needs ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Read more here.

This strategic move enhances Tempus AI's market position and service offerings by expanding its diagnostic capabilities, particularly in hereditary cancer screening and genetic testing for various ...